SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06500.0%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dirkdiggler who wrote (12075)6/12/2013 5:54:39 PM
From: boomertree22 Recommendations

Recommended By
Bradpalm1
Pogeu Mahone

  Read Replies (3) of 13111
 
Phase III drug trials can easily cost in the 100's of millions of dollars. I have seen estimates given for the modest 180 patient PV-10 phase III trial at $9 to $15 million. The Company presently only has $5 million. If you look at the Company historical annual cash burn rate, more money has been spent on executive officer compensation then has been spent on the trials thus far, which accounts for the insufficient funds to pay for the phase III trial. Given the huge amount of cheap stock options the officers also paid themselves (which is the subject of a current stockholder derivative lawsuit), one would think that the officers would be willing to accept the same deferred potential stock appreciation benefit and risk as the long shareholders, rather than plunder insufficient Company cash resources to pay themselves immediate egregious cash compensation. Their greed has put the future success of the Company at risk.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News